Prostate-specific antigen testing in hypogonadism: Implications for the safety of testosterone-replacement therapy

BJU International

Volumn 98, Issue 1, 2006, Pages 1-4

  Gould, Duncan C ^a   Feneley, Mark R ^b   Kirby, Roger S ^a  

^a Prostate Centre   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hypogonadism; Prostate cancer; PSA; Testosterone; uPM3

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANTIGEN SPECIFICITY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INVASION; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CONTRAINDICATION; EARLY DIAGNOSIS; GENDER; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALIGNANT TRANSFORMATION; MEASUREMENT; ORGAN SIZE; PATIENT MONITORING; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 33745066505     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06191.x     Document Type: Review

References (28)

1. Rhoden EL Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003 170: 2348 51
2. Morales A Lunenfeld B, International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002 5: 74 86
3. Nieschlag E Swerdloff R Behre HM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. Int J Androl 2005 28: 125 7
4. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002 8: 440 56
5. Behre HM Bohmeyer J Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994 40: 341 9
6. Hoffman MA DeWolf WC Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000 163: 824 7
7. Morgentaler A Bruning CO3rd DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996 276: 1904 6
8. Rhoden EL Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004 350: 482 92
9. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992 75: 1092 8
10. Hajjar RR Kaiser FE Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997 82: 3793 6
11. Dobs AS Meikle AW Arver S Sanders SW Caramelli KE Mazer NA. Pharmacokinetics, efficacy and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999 84: 3469 78
12. Sih R Morley JE Kaiser FE Perry HM rd, Patrick P Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomised controlled trial. J Clin Endocrinol Metab 1997 82: 1661 7
13. Guay AT Perez JB Fitaihi WA Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract 2000 6: 132 8
14. von Eckardstein S Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002 23: 419 25
15. Svetec DA Canby ED Thomson IM Sabanegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997 158: 1775 7
16. Kenny AM Prestwood KM Gruman CA Marcello KM Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerentol A Biol Sci Med Sci 2001 56: M266 72
17. Wang C Swerdloff RS Iranmanesh A et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000 85: 2839 53
18. Dean JD Carnegie C Rodzvilla J Jr, Smith T. Long-term effects of Testim 1% testosterone gel in hypogonadal men. Rev Urol 2004 6 ( Suppl. 6 S22 29
19. Gerstenbluth RE Maniam PN Corty EW Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002 23: 922 6
20. Snyder PJ Peachey H Hannoush P et al. Effect of testosterone on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999 84: 1966 72
21. Wang C Cunningham G Dobs A et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004 89: 2085 98
22. Steidle C Schwartz S Jacoby K Sebree T Smith T Bachand R North American AA 2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metabol 2003 88: 2673 81
23. Nieschlag E Buchter D von Eckardstein S Abshagen K Simoni M Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999 51: 757 63
24. Tan RS Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 2003 6: 13 7
25. Rhoden EL Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2005 18: 201 5
26. Bhasin S Singh AB Mac P Carter B Lee MI Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003 24: 299 311
27. Fradet Y Saad F Aprikian A et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004 64: 311 6
28. Tinzl M Marberger M Horvath S Chypre C. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004 46: 182 7